Postby GrouseMan » Tue Aug 06, 2024 12:03 pm
Recently - I saw a study where they finally pinned down the cause of the skin rash caused by the EGFr inhibitor class of drugs. I once worked on this class some time ago, and our first investigational small molecule EGFr inhibitor to alleviate the rash Benadryl was used during the clinical trials. Lately antibiotic drugs have been prescribed and they are helpful. My wife was on Cephalexin twice a day while on Erbutux (Cetuximab) which is a monoclonal antibody. The latest research suggests that inhibition of EGFr can activate Keratinocytes which result in the expression of cytokines, Chemokines and IL6 through the activation of the JAK STAT pathway.
In a pilot clinical trial they have found that topical treatment with a JAK inhibitor ointment (delgocitinib) resulted in improvement in rash severity.
See the following articles about EGFr inhibitors and Rash:
An Early study from June 2018 in Cliical Colorectal Cancer V17, Issue 2 p 85-97.
https://www.sciencedirect.com/science/a ... 281630278XAnother inhibitor (this time of CCL5 expression) see: Scientific Reports V 13 Article Number 22102 (December 2023).
https://www.nature.com/articles/s41598-023-49627-8 and finally the latest one about JAK inhibition from Science Translational Medicine Vol 16 No. 752 19 Jun2 2024:
https://www.science.org/doi/10.1126/sci ... ed.abq7074Regards,
GrouseMan
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017